logo
Starmer thanks NHS worker who looked after his brother

Starmer thanks NHS worker who looked after his brother

Yahoo3 hours ago
The Prime Minister has thanked an NHS worker who looked after his brother in the last weeks of his life.
Sir Keir Starmer's brother Nick died on Boxing Day in 2024 aged 60, having been ill with cancer.
In a video posted on social media to mark the 77th anniversary of the health service, the PM said that advanced nurse practitioner Ben Huntley made sure that his brother 'felt cared for and respected'.
In the clip, Sir Keir is shown speaking to Mr Huntley in Downing Street, while other members of the public also meet with NHS staff who helped them.
The NHS has always been there for my family.
Today, on its 77th anniversary, the entire country says thank you. pic.twitter.com/1txKPMwx1d
— Keir Starmer (@Keir_Starmer) July 5, 2025
The Prime Minister said: 'My mum worked in the NHS and then she was very, very ill, for most of her life. And the NHS became our absolute lifeline.
'My sister worked for the NHS, my wife works for the NHS, and it was the NHS that looked after my brother who we lost last Boxing Day to cancer.
'Ben, you looked after him. I think from the moment he was in all the way through, and you made sure that he felt cared for and respected.'
The PM later added: 'That meant a huge amount to me and my family and, on all of our behalves, I say through you a very special thank you to the NHS.'
Earlier this week, Sir Keir told the BBC's Political Thinking that he 'made it my business to be there in the hospital' when his brother was told about his diagnosis 'so that I could begin to help look after him'.
'It's really hard to lose your brother to cancer, he was a very vulnerable man,' the Prime Minister said.
He shared details of 'going up in the porter's lift into the back of the intensive care unit' and wanting to protect his brother's privacy.
He told the same interview that US President Donald Trump asked about his brother in a call a 'few days' after he died.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update
Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update

Yahoo

time42 minutes ago

  • Yahoo

Piper Sandler Reaffirms Buy on Amgen Amid MariTide Tolerability Update

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc. (NASDAQ:AMGN) in response to the company's disclosure of comprehensive MariTide tolerability data. 360b / The obesity medication's gastrointestinal tolerability profile unnerved the market, particularly the frequency of nausea and vomiting, which at first seemed more problematic than alternatives. Piper Sandler's study however, shows that both one- and two-step dose escalation regimens showed a noticeable improvement in the drug's tolerability profile, consistent with management's claims at the December top-line results announcement. According to the firm, the weight loss drug could produce a more commercially acceptable nausea and vomiting profile due to the much lower starting dosages and three-step dose escalation protocols included in the pivotal studies. Amgen Inc. (NASDAQ:AMGN) is a global biopharmaceutical company that focuses on human treatments for cardiovascular, hematology, inflammation, cancer, and bone health. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Stryker's Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy
Stryker's Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy

Yahoo

time42 minutes ago

  • Yahoo

Stryker's Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy

Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy. On June 25, Stryker Corporation (NYSE:SYK) announced that its Incompass Total Ankle System, intended for patients with severe rheumatoid, post-traumatic, or degenerative arthritis-related ankle joint damage, received FDA 510(k) clearance. The Incompass system integrates Adaptis Boney Ingrowth Technology and revised instrumentation to facilitate long-term fixation, surgical flexibility, and optimized workflow. According to the company, data from 100,000 clinical cases and over 85,000 CT scans were used in guiding the system's development. Additionally, in support of the company's strategic direction, Stryker Corporation (NYSE:SYK) shareholders recently approved revisions to key incentive plans, such as the 2008 Employee Stock Purchase Plan and the 2011 Long-Term Incentive Plan. Founded in 1981, Stryker Corporation (NYSE:SYK) is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopaedics, MedSurg, and Neurotechnology and Spine. While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Inicia sesión para acceder a tu portafolio

UBS Lowers UNH Target Amid Conservative 2025 Outlook from CEO
UBS Lowers UNH Target Amid Conservative 2025 Outlook from CEO

Yahoo

time42 minutes ago

  • Yahoo

UBS Lowers UNH Target Amid Conservative 2025 Outlook from CEO

UnitedHealth Group Incorporated (NYSE:UNH) ranks among the best set-it-and-forget-it stocks to buy. While maintaining its Buy rating, UBS reduced its price target for UnitedHealth Group Incorporated (NYSE:UNH) from $400 to $385 on June 25. The adjustment followed remarks made by UnitedHealth's returning CEO at the company's June 2 annual meeting, when he stated that management would restore its 2025 projection during the second-quarter earnings release on July 29. Ken Wolter/ UBS pointed out that the investment community has taken CEO Hemsley's description of the forecast as 'prudent' as a hint that guidance would be more conservative than the consensus of $22.50 earnings per share set on June 2. UBS recently revised its own predictions to reflect the recent movement in investor expectations toward a $20 EPS estimate for 2025. UnitedHealth Group Incorporated (NYSE:UNH) is a renowned US multinational corporation that provides managed healthcare and insurance services. The company operates through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store